29 November 2022 |
29 November 2022
AGM Results
|
29 November 2022 |
29 November 2022
Retirement of non-executive director
|
29 November 2022 |
29 November 2022
AGM Chairman’s address and CEO’s presentation
|
22 November 2022 |
22 November 2022
Viraleze launched in Hong Kong and Macau
|
8 November 2022 |
8 November 2022
Starpharma to present at Bell Potter Healthcare Conference
|
31 October 2022 |
31 October 2022
Appendix 3Y
|
31 October 2022 |
31 October 2022
Appendix 3Y
|
28 October 2022 |
28 October 2022
2022 SPL Notice of AGM and Proxy Form
|
27 October 2022 |
27 October 2022
Appendix 2A
|
27 October 2022 |
27 October 2022
Appendix 2A
|
27 October 2022 |
27 October 2022
Appendix 3G
|
26 October 2022 |
26 October 2022
Quarterly Activities Report & Appendix 4C
|
21 October 2022 |
21 October 2022
VIRALEZE™ distribution agreement for Hong Kong and Macau
|
21 October 2022 |
21 October 2022
Change in Substantial Holder
|
7 October 2022 |
7 October 2022
Appendix 3Y
|
7 October 2022 |
7 October 2022
Appendix 3H
|
5 October 2022 |
5 October 2022
Board Renewal
|
30 September 2022 |
30 September 2022
Starpharma Date of 2022 AGM
|
15 September 2022 |
15 September 2022
Starpharma to present at Life Sciences Investor Forum
|
12 September 2022 |
12 September 2022
Change in Substantial Holder - Allan Gray
|
Investor Relations
For general questions about Starpharma Holdings Limited, please contact us at:
T: +61 3 8532 2700
E: investor.relations@starpharma.com